<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Nurmohamed, Michael T.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Anti-TNF Therapy and CV Risk in RA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Systemic inflammation in patients with rheumatoid arthritis (RA) leads to a greater risk of cardiovascular (CV) events that are linked to tumor necrosis factor (TNF)-related atherogenesis. Anti-TNF therapies have been shown in observational studies to reduce the risk of CV events in patients with RA. The objective of this retrospective medical record review was to compare the effect of exposure to anti-TNF treatment on the risk of CV events in patients with RA with those who were treated with methotrexate and other disease-modifying therapies.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>